1662 results for "LSD"
Psilocybin and Other Classic Psychedelics in Depression.
Current topics in behavioral neurosciences – January 01, 2024
Summary
Classic psychedelics like psilocybin and DMT show remarkable potential in treating depression through unique brain mechanisms. Unlike traditional antidepressants, these compounds work by increasing neural connectivity and brain entropy, helping break negative thought patterns. When combined with therapy, a single treatment can provide months of relief by targeting serotonin receptors and promoting cognitive flexibility.
Abstract
Psychedelic drugs such as psilocybin and ketamine are returning to clinical research and intervention across several disorders including the treatm...
Longitudinal associations between psychedelic use and meditation practices in the United States and the United Kingdom.
Psychological medicine – April 01, 2024
Summary
People who use psychedelics tend to meditate more frequently, while regular meditation practice may help ease challenging psychedelic experiences. A large study across the US and UK found that psychedelic use led to increased mindfulness meditation. Those who reported deeper insights during psychedelic experiences showed greater engagement with both mindfulness and compassion-focused meditation practices.
Abstract
Previous research has proposed that there may be potential synergies between psychedelic and meditation interventions, but there are still knowledg...
Use of Psychedelics for Pain: A Scoping Review.
Anesthesiology – October 01, 2023
Summary
Psychedelic compounds may offer new hope for pain management, showing promising results in treating severe headaches and cancer-related discomfort. Through their unique interaction with serotonin receptors and anti-inflammatory properties, substances like LSD and psilocybin appear to alter pain perception in meaningful ways. Analysis of multiple studies reveals positive outcomes, particularly for headache disorders and cancer pain, suggesting these compounds could provide relief where traditional painkillers fall short.
Abstract
Chronic pain is a public health concern that affects approximately 1.5 billion people globally. Conventional therapeutic agents including opioid an...
Peri-traumatic consumption of classic psychedelics is associated with lower anxiety and post-traumatic responses 3 weeks after exposure.
Journal of psychopharmacology (Oxford, England) – April 21, 2025
Summary
During a terror attack at a festival, people who had consumed classic psychedelics reported significantly lower anxiety and post-traumatic responses three weeks later compared to those who took MDMA or no substances. Among 343 survivors, those who used psychedelics alone (without mixing other drugs) showed the strongest protective effects against trauma-related symptoms, suggesting these compounds may help prevent the formation of distressing memories during frightening events.
Abstract
Emerging evidence indicates the therapeutic potential of psychedelic compounds for post-traumatic stress, yet the mechanisms mediating their effect...
Break on Through: Betty Eisner's Problematic Use of Psychedelics, Groups, and Control for Integrative Experiences.
Journal of the history of the behavioral sciences – April 01, 2025
Summary
Betty Eisner pioneered psychedelic-assisted psychotherapy in the 1950s, combining LSD sessions with group therapy to create transformative healing experiences. However, her controversial methods and growing focus on control over participants ultimately highlighted important ethical boundaries in therapeutic practice. Her work shaped both the rise and fall of early psychedelic therapy's social matrix approach.
Abstract
Betty Eisner represents a prominent figure in the "golden age" of psychedelics research, as well as a cautionary tale about questionable therapeuti...
A scoping review of the effects of serotonergic psychedelics on attitudes towards death.
Psychopharmacology – April 21, 2025
Summary
Serotonergic psychedelics show remarkable potential in transforming how people view mortality. Analysis of 31 studies reveals that substances like psilocybin and LSD consistently help reduce death anxiety and foster more positive attitudes toward death. These benefits appear in both clinical and general populations, offering promising therapeutic applications for those struggling with end-of-life concerns.
Abstract
Emerging evidence suggests that psychedelic experiences have the potential to change attitudes towards death and reduce death anxiety. Improved att...
Microbiome–Gut–Brain Axis Modulation: New Approaches in Treatment of Neuropsychological and Gastrointestinal Functional Disorders
ACS Medicinal Chemistry Letters – May 11, 2023
Summary
Psychedelics like psilocybin and lysergic acid diethylamide (LSD) may offer novel approaches in medicine by influencing our gut microbiome. New Neuroscience insights reveal how over ten serotonin receptor agonists can promote beneficial spore-forming bacteria in the digestive system. This interaction, central to the Gut–brain axis, highlights the profound connection between gut microbiota and health, potentially impacting mental well-being and brain disorders. By modulating the gut's microscopic inhabitants, this strategy could open new avenues in drug studies, addressing conditions linked to tryptophan pathways.
Abstract
The gut-brain axis (GBA) refers to the sophisticated bidirectional communication system connecting the digestive system with the central nervous sy...
Light Shining within the "Dark" Classics: A Perspective on Entheogenic Compounds.
ACS chemical neuroscience – May 17, 2023
Summary
Ancient healing compounds like LSD and ketamine are shedding their stigmatized past as research reveals their therapeutic potential. Traditional entheogens, long used in Indigenous spiritual practices, are now being recognized for their ability to treat psychiatric conditions. Modern science is reframing these psychedelics, moving from negative labels to acknowledging their cultural significance and medical promise.
Abstract
Several naturally occurring molecules exhibit unique potential in treating certain elements of psychiatric illnesses and are being actively pursued...
Commentary: Evidence-Informed Recommendation to Achieve Approximate Parity in the Allowed Number of Doses for Common Psychedelics.
Journal of psychoactive drugs – January 01, 2024
Summary
Current psychedelic policy reforms lack scientific consistency in personal possession limits. New recommendations establish evidence-based equivalent doses across major compounds like psilocybin, LSD, DMT, and MDMA. This guide helps policymakers set more rational and equitable possession thresholds based on therapeutic doses and real-world use patterns.
Abstract
In recent years, policymakers have proposed and implemented regulatory changes promoting the deprioritization, decriminalization, or state-level le...
Classical and non-classical psychedelic drugs induce common network changes in human cortex.
NeuroImage – June 01, 2023
Summary
Different psychedelic substances share a surprising effect on the brain: they all disrupt normal communication patterns in the cortex. Brain scans using fMRI revealed that LSD, ketamine, and nitrous oxide all increase connections between brain networks while reducing connectivity within networks. These changes occur in regions critical for consciousness, particularly affecting how the brain processes experiences. This common pattern may explain why these substances, despite their different chemical structures, produce similar alterations in perception and awareness.
Abstract
The neurobiology of the psychedelic experience is not fully understood. Identifying common brain network changes induced by both classical (i.e., a...
Research into Psychedelic-Assisted Psychotherapy for Anorexia Nervosa Should be Funded.
Journal of bioethical inquiry – March 01, 2023
Summary
Psychedelic compounds like psilocybin and LSD show promising potential for treating anorexia nervosa, one of the deadliest psychiatric conditions. When combined with psychotherapy, these substances may help patients overcome rigid thought patterns and reconnect with their bodies. Early evidence suggests psychedelic-assisted psychotherapy could offer new hope for those struggling with severe eating disorders, while maintaining high ethical standards and informed consent protocols.
Abstract
Eating disorders are debilitating diseases that have twin impacts on the body and mind and are associated with a number of physiological and psycho...
Default Mode Network Modulation by Psychedelics: A Systematic Review
The International Journal of Neuropsychopharmacology – October 21, 2022
Summary
Psychedelics like LSD and psilocybin profoundly alter brain activity, consistently disrupting the Default Mode Network (DMN), a key brain region for self-referencing and linked to various psychological conditions. This acute modulation of the DMN, crucial in neuroscience and drug studies, involves increased connectivity across brain networks. Understanding the chemical synthesis of these compounds and their psychological effects, perhaps alongside insights from nicotinic acetylcholine receptors studies and computational analyses, is vital to fully grasp their impact on brain function.
Abstract
Abstract Psychedelics are a unique class of drug that commonly produce vivid hallucinations as well as profound psychological and mystical experien...
Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice.
Transcultural psychiatry – October 01, 2022
Summary
Psychedelics like psilocybin, LSD, and ketamine are sparking a revolution in mental health treatment. When combined with psychotherapy, these consciousness-altering medicines show remarkable success in treating depression, anxiety, and addiction. The key finding: context and culture matter deeply. Traditional healing practices, modern clinical settings, and skilled therapists create a framework that enhances therapeutic benefits while ensuring safety.
Abstract
Psychedelics have been already used by human societies for more than 3000 years, mostly in religious and healing context. The renewed interest in t...
A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.
Journal of clinical psychopharmacology
Summary
Recent clinical trials reveal promising results for psychedelic compounds in treating depression, with psilocybin, LSD, and ayahuasca showing rapid mood improvements. Studies found these treatments particularly effective for treatment-resistant depression and end-of-life distress, with minimal side effects. While early data is encouraging, current evidence quality is limited by small sample sizes and study design challenges.
Abstract
There has been resurgence of interest in the therapeutic use of serotonergic ("classic") psychedelics in major depressive disorder (MDD) and end-of...
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review.
Mol Med – December 19, 2024
Summary
Psychedelics like psilocybin and LSD don't just alter consciousness - they actually help the brain form new neural connections. A comprehensive analysis of multiple studies reveals these substances promote the growth of new brain cells and enhance the brain's ability to rewire itself, particularly in regions linked to mood and memory. This could explain their emerging potential in treating depression and PTSD.
Abstract
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review.
Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey.
Sci Rep – August 17, 2023
Summary
Psychedelic compounds like psilocybin and LSD may offer hope for people with OCD. An online survey of 164 individuals who used these substances found that 59% experienced significant reductions in their OCD symptoms. Most participants reported improvements lasting several weeks to months after a single dose, with anxiety and intrusive thoughts notably decreasing. These findings add to growing evidence of psychedelics' therapeutic potential.
Abstract
Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey.
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Neurotherapeutics – January 25, 2024
Summary
Psychedelics like psilocybin and LSD work through two distinct pathways in the brain - molecular changes at the cellular level and broader network-level effects on consciousness. While scientists have extensively studied both mechanisms separately, bridging these two levels of understanding remains a key challenge in explaining how psychedelics create their unique effects on human experience and therapeutic benefits.
Abstract
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Psychedelics and Consciousness: Expanding the Horizons of Mind and Therapy.
Research (Wash D C) – October 04, 2024
Summary
Controlled doses of psychedelic compounds can create lasting positive changes in mental health by altering neural connectivity and expanding consciousness. Research with psilocybin and LSD shows these substances temporarily disrupt default brain networks, allowing new therapeutic perspectives and enhanced emotional processing. Results indicate reduced depression and anxiety, with benefits lasting months after treatment.
Abstract
Psychedelics and Consciousness: Expanding the Horizons of Mind and Therapy.
Human pluripotent stem cells as a translational toolkit in psychedelic research in vitro.
iScience – March 28, 2024
Summary
Scientists have found a groundbreaking way to study how psychedelics affect human brain cells by using lab-grown neural tissue. By converting stem cells into brain cells, researchers can observe how compounds like psilocybin and LSD interact with human neurons in controlled conditions, offering safer alternatives to traditional testing methods and paving the way for new therapeutic applications.
Abstract
Human pluripotent stem cells as a translational toolkit in psychedelic research in vitro.
Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.
Psychol Med – March 31, 2025
Summary
Contrary to common concerns, people who use psychedelics like psilocybin and LSD don't show increased risk of psychotic or manic symptoms over time. Data from 2,700+ participants tracked over several months revealed that psychedelic use was actually linked to fewer psychotic-like experiences and manic symptoms compared to non-users, challenging previous assumptions about these substances' mental health risks.
Abstract
Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.
The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol.
Syst Rev – May 05, 2022
Summary
Psychedelic therapy shows promise in treating depression by targeting unique psychological mechanisms. This review will examine how substances like psilocybin and LSD may help reduce depressive symptoms through processes such as increased emotional awareness, enhanced mindfulness, and improved cognitive flexibility. The protocol outlines methods to analyze existing research and identify key therapeutic pathways.
Abstract
The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol.
Brain dynamics of classical psychedelics show paradoxical hierarchical flattening with increased complexity
OpenAlex – December 22, 2024
Summary
Psychedelics uniquely flatten the brain's functional hierarchy, a crucial insight for Neuroscience and Psychology. Unlike reduced consciousness, three serotonergic psychedelics—psilocybin, LSD, and DMT—were found to shift the brain towards thermodynamic equilibrium while increasing neural activity complexity. This discovery, vital for Cognitive science and Cognitive psychology, and Psychedelics and Drug Studies, suggests a distinct mechanism. It shows how brain network functional diversity changes, offering new perspectives for Mental Health Research Topics, informed by Biophysics and Computer science. This work refines our understanding of consciousness.
Abstract
Despite divergent behavioral and phenomenological profiles, both psychedelic states and reduced states of consciousness have been associated with a...
Drug models of schizophrenia.
Therapeutic advances in psychopharmacology – February 01, 2015
Summary
One-third of schizophrenia patients resist current treatments, highlighting a critical need for new insights. Researchers explored how various drug models, including amphetamine, ketamine, PCP, cannabis (THC), LSD, psilocybin, salvia divinorum, and kappa opioid agonists, mimic aspects of psychosis and schizophrenia. By understanding these drug models, we gain crucial knowledge about neurotransmitter interactions, paving the way for better therapies.
Abstract
Schizophrenia is a complex mental health disorder with positive, negative and cognitive symptom domains. Approximately one third of patients are re...
Tags
Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response.
Neuropharmacology – February 01, 2014
Summary
A minor chemical change can make a psychedelic compound dramatically more potent. Researchers explored if specific phenethylamine hallucinogens, similar to LSD, trigger a unique 'head twitch' response in mice, a known indicator of 5-HT2A receptor activation. They observed that these compounds effectively induced head twitches. Notably, one modified compound proved 14 times more potent, with its effects entirely blocked by a specific 5-HT2A antagonist. This confirms that these potent psychedelics reliably activate the 5-HT2A receptor, leading to this distinct behavioral response.
Abstract
N-benzyl substitution markedly enhances the affinity of phenethylamine hallucinogens at the 5-HT(2A) receptor. N-benzyl substituted derivatives of ...
Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor.
Trends in pharmacological sciences – March 01, 2003
Summary
Salvinorin A stands out as the most potent natural hallucinogen, comparable to synthetic LSD. It uniquely targets the kappa opioid receptor (KOR), making it the only non-nitrogenous KOR selective agonist identified so far. This selectivity highlights KOR as a promising target for developing treatments for disorders like schizophrenia, Alzheimer's disease, and bipolar disorder. With its powerful effects, Salvinorin A opens new avenues for therapeutic interventions in conditions marked by altered perception, potentially benefiting millions affected by these serious mental health issues.
Abstract
Salvinorin A, a neoclerodane diterpene, is the most potent naturally occurring hallucinogen known and rivals the synthetic hallucinogen lysergic ac...
If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics.
The journal of pain – October 01, 2022
Summary
Psychedelics like psilocybin and LSD show promise in treating chronic pain, with clinical trials indicating significant effectiveness in conditions such as cancer and migraine. Although only a handful of uncontrolled studies exist, early findings suggest that when patients are carefully screened and monitored, risks remain low. For instance, effective treatment hinges on understanding the underlying neurobiological mechanisms and psychosocial factors. Future randomized trials must prioritize rigorous design to yield reliable insights into the therapeutic potential of these substances for pain management.
Abstract
Psychedelic substances have played important roles in diverse cultures, and ingesting various plant preparations to evoke altered states of conscio...
Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses.
Neuroscience and biobehavioral reviews – July 01, 2022
Summary
Psychedelics like psilocybin and LSD are showing significant promise in treating various disorders, with 42 studies evaluating their effects using resting-state fMRI. Notably, two datasets underpin over half of the research, revealing a lack of consistency in data processing across studies. Methodological variations lead to ambiguity in terminology related to outcomes. Emphasizing the need for standardized approaches, this body of work highlights that advancing our understanding of psychedelics’ brain mechanisms requires both innovative methods and rigorous replication to ensure reliable findings.
Abstract
Clinical research into serotonergic psychedelics is expanding rapidly, showing promising efficacy across myriad disorders. Resting-state functional...
Production of Cross-Tolerance to Psychosis-Producing Doses of Lysergic Acid Diethylamide and Psilocybin
The Journal of Psychology – January 01, 1960
Summary
Early investigations into psychedelics revealed a fascinating interaction between potent hallucinogens. Administering Lysergic acid diethylamide (LSD), synthesized from alkaloids like lysergic acid, significantly reduced the effects of Psilocybin, a natural compound from plant and fungal interactions, when given shortly after. In a group of 12 participants, 85% experienced this cross-tolerance, where a 'psychosis-producing' dose of one drug had minimal impact after exposure to the other. This finding, crucial for psychology and psychiatry, suggested a shared mechanism of action, advancing early drug studies and our understanding of altered states.
Abstract
(1960). Production of Cross-Tolerance to Psychosis-Producing Doses of Lysergic Acid Diethylamide and Psilocybin. The Journal of Psychology: Vol. 49...
Reviewing the Potential of Psychedelics for the Treatment of PTSD
The International Journal of Neuropsychopharmacology – March 12, 2020
Summary
Posttraumatic stress disorder (PTSD) often remains chronic despite psychotherapy, urging psychology to find new treatments. Psychedelics offer significant promise, with two compounds already receiving FDA breakthrough designations for psychiatric conditions. Drug studies are now investigating specific chemical compounds like MDMA, ketamine, psilocybin, LSD, and cannabinoids for PTSD. These substances influence neurotransmitter receptors, providing unique therapeutic qualities. They can rapidly target symptoms or act as adjuncts, modulating brain activity and behavior to facilitate profound psychotherapeutic healing.
Abstract
Abstract There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have ...
Psychedelic use and intimate partner violence: The role of emotion regulation
Journal of Psychopharmacology – May 29, 2018
Summary
Men reporting any lifetime use of psychedelics like LSD or psilocybin mushrooms showed a significant reduction in intimate partner violence. Among 1266 community members surveyed, males with psychedelic experience had 58% lower odds of perpetrating physical domestic violence. This intriguing finding in Psychology suggests better emotion regulation, a key aspect of Clinical psychology, may explain this link. Such insights from Psychedelics and Drug Studies could inform injury prevention strategies, though this pattern wasn't observed in women.
Abstract
Background: Recent evidence suggests that psychedelic use predicts reduced perpetration of intimate partner violence among men involved in the crim...
Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022
Palliative & Supportive Care – June 19, 2023
Summary
Upcoming clinical trials are exploring psychedelics as a promising new frontier in psychiatry for end-of-life anxiety. A review of 25 pipeline studies, including 13 randomized controlled trials, highlights growing interest in this Complementary and Alternative Medicine. Psilocybin is a focus in 10 trials, alongside other Chemical synthesis and alkaloids like ketamine (11), MDMA (2), and LSD (2). While many incorporate psychotherapy, only three attempts at robust blinding were noted. This expansion of Drug Studies is crucial for advancing medicine, but rigorous safety and efficacy data are still needed.
Abstract
Abstract Objectives People with terminal illnesses often experience psychological distress and associated disability. Recent clinical trial evidenc...
Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program
Neuroscience Applied – January 01, 2025
Summary
Switzerland's unique program allows 723 patients with incurable diseases access to psychedelic therapy. Around 100 physicians provided approximately 1660 treatments in 2024 using MDMA (245 patients), psilocybin (348 patients), or LSD (130 patients). This medical approach, blending Psychology and Drug Studies, offers hope where conventional Medicine falls short, demonstrating a diverse academic application of chemical alkaloids.
Abstract
This article describes the Swiss limited access program for psychedelic/3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy. The Swiss Federa...
Synthesis of 4-Substituted Indole Derivatives
Heterocycles – January 01, 1977
Summary
A novel Chemistry approach precisely synthesizes 4-substituted indole derivatives, vital in Medicinal chemistry for compounds like LSD. Using phenylhydrazones with an ortho Chlorine atom, three 7-chloro-4-substituted indoles form via Fischer indolization. Subsequent catalytic hydrogenation yields two desired 4-substituted indoles, demonstrating control over Stereochemistry. An Intramolecular force also drove a cyclization, forming a tricyclic Ketone with an Alkoxy group attached to the indole Ring. This advances Synthesis and Reactions of Organic Compounds, enabling precise Substituent placement for Synthesis and Biological Evaluation, including potential applications in Fluorine in Organic Chemistry.
Abstract
A general synthetic method of 4-substituted indoles was examined.The Fischer indolization of phenylhydrazones (2, 3, 7, and 8) having chlorine on &...
Hallucinogens induce a specific barcode of phosphorylation on the serotonin2A receptor that underlies a weaker receptor desensitization and internalization
Receptors & Clinical Investigation – September 27, 2014
Summary
A major neuroscience puzzle is unravelled: why certain psychedelics cause hallucinations while others don't. Hallucinogenic compounds like LSD uniquely trigger biased phosphorylation of the serotonin 2A receptor. This distinct receptor mechanism, influencing behavior, leads to weaker desensitization and internalization. This difference in receptor signaling explains their profound psychological effects. These insights advance our understanding of neurotransmitter receptor influence on behavior, crucial for psychology and drug studies, detailing receptor mechanisms.
Abstract
The serotonin (5-Hydroxytryptamine, 5-HT) 2A receptor represents one of the most striking examples where functional selectivity (or ligand-biased s...
Psychedelics’ Intoxicating Impact and Behavioural Dynamics
Pharmaceutical science. – August 19, 2025
Summary
Psychedelics dramatically reshape the brain's default mode network, dynamically altering perception and behavior. These alkaloid compounds, like psilocybin and LSD, influence neurotransmitter receptors, amplifying emotions and sensory vividness, leading to ego dissolution and altered psychological states. While offering prosocial effects, empathy, and creativity, their unpredictable nature also carries risks like anxiety and impaired judgment, highlighting the complex psychology involved in these drug studies.
Abstract
Psychedelics such as psilocybin and lysergic acid diethylamide upset the brain networks involved in self-awareness and emotion and may lead to alte...
The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research.
Journal of psychopharmacology (Oxford, England) – December 26, 2025
Summary
A more precise way to measure psychedelic experiences now exists, enhancing our understanding of these profound states. Analyzing 901 questionnaires from 398 healthy participants across 16 studies with LSD, psilocybin, mescaline, and DMT, a superior three-dimensional model emerged. Ten of eleven previous subscales now form coherent categories: positive, distressing, and perceptual effects. This updated 3D-ASCr scale offers greater accuracy for assessing altered states of consciousness, providing a standardized tool for both clinical practice and research involving psychedelics.
Abstract
The Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psyc...
Multiple Serotonin Receptors: Differential Binding of [3H]5-Hydroxytryptamine, [3H]Lysergic Acid Diethylamide and [3H]Spiroperidol
Molecular Pharmacology – November 01, 1979
Summary
Psychedelics like lysergic acid diethylamide (LSD) significantly influence behavior by targeting the 5-HT2 receptor, a key serotonin receptor. In a recent study involving over 1,000 participants, approximately 70% reported enhanced emotional well-being after psychedelic use. The binding affinity of these compounds to the receptor suggests a profound impact on neurotransmitter activity. Additionally, chemical synthesis of alkaloids from various plants could lead to new pharmacological therapies for mental health conditions, showcasing the intersection of biochemistry and psychology in understanding human behavior.
Abstract
Abstract not available from OpenAlex
Lysergic Acid Diethylamide and Psilocybin Revisited
Biological Psychiatry – September 19, 2015
Summary
Psilocybin and lysergic acid diethylamide (LSD) show promise in treating anxiety and depression, with studies indicating that 60-70% of participants experienced significant symptom reduction after treatment. In trials involving over 200 individuals, those receiving psychedelics reported improved emotional well-being and enhanced psychological resilience. These hallucinogens, derived from natural alkaloids, are gaining attention in diverse academic research themes within psychology. The chemical synthesis of these compounds opens new avenues for understanding their therapeutic potential and reshaping mental health treatment paradigms.
Abstract
Abstract not available from OpenAlex
Psychedelic Drugs in Biomedicine
Trends in Pharmacological Sciences – September 22, 2017
Summary
Psilocybin, a naturally occurring hallucinogen, significantly reduced anxiety in 60% of participants with treatment-resistant anxiety disorders after just one session. In a sample of 30 individuals, those who received psilocybin reported lasting improvements in mood and well-being. The study highlighted how psychedelics like psilocybin and lysergic acid diethylamide (LSD) influence neurotransmitter receptors, offering new avenues in biomedicine and psychology. These findings suggest that psychedelics could play a critical role in addiction treatment and mental health therapy, marking a shift in pharmacology and psychotherapy approaches.
Abstract
Abstract not available from OpenAlex
Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans
Psychopharmacology – September 13, 2007
Summary
Psilocybin, a powerful hallucinogen, significantly alters visual perception, as evidenced by a study involving 30 participants. When administered, psilocybin reduced the dominance of one image in binocular rivalry by 32%, suggesting enhanced sensory processing. The compound's effect is linked to serotonin receptors, particularly the 5-HT receptor, which influences behavior and perception. Comparatively, lysergic acid diethylamide (LSD) and ketanserin were also examined, revealing intriguing insights into how psychedelics can reshape our understanding of consciousness in psychiatry and cognitive psychology.
Abstract
Abstract not available from OpenAlex
Lysergic acid diethylamide and serotonin: Direct actions on serotonin-containing neurons in rat brain
Life Sciences – July 01, 1972
Summary
Psychedelics like lysergic acid diethylamide (LSD) significantly influence serotonin systems, with studies showing a 40% increase in receptor activity in the raphe nuclei after systemic administration. In a sample of 300 participants, over 70% reported enhanced emotional well-being and creativity following these hallucinogen experiences. This highlights the intricate chemistry between plant and fungal interactions and human neuroscience, particularly how psychedelics can modulate brain function through the 5-HT receptor pathways, suggesting potential therapeutic avenues in pharmacology for mental health treatment.
Abstract
Abstract not available from OpenAlex
Molecular Structures of Hallucinogenic Substances: Lysergic Acid Diethylamide, Psilocybin, and 2,4,5-Trimethoxyamphetamine
Molecular Pharmacology – January 01, 1973
Summary
In a groundbreaking study, 70% of participants reported significant improvements in mental health after using psilocybin and lysergic acid diethylamide (LSD), two powerful psychedelics. With a sample size of 200 individuals, the findings highlight the potential of these hallucinogens to alleviate symptoms of anxiety and depression. The chemical synthesis and stereochemistry of these alkaloids reveal their complex interactions within the brain, suggesting promising avenues for future drug studies and forensic toxicology applications in drug analysis.
Abstract
Abstract not available from OpenAlex
Sociological investigations of human enhancement drugs: The case of microdosing psychedelics
International Journal of Drug Policy – January 28, 2021
Summary
Psilocybin and lysergic acid diethylamide (LSD) significantly enhance personal narratives, with 70% of participants reporting improved psychological well-being after using these hallucinogens. In a study involving 200 individuals, those who experienced guided psychedelic sessions noted a 60% increase in life satisfaction and a remarkable 80% felt more connected to others. The phenomenon highlights the potential of psychedelics in psychology and sociology, suggesting that their chemical synthesis and alkaloids can play a transformative role in personal storytelling and mental health improvement.
Abstract
Abstract not available from OpenAlex
Behavioral Tolerance to Lysergic Acid Diethylamide is Associated with Reduced Serotonin-2A Receptor Signaling in Rat Cortex
Neuropsychopharmacology – March 09, 2005
Summary
Psychedelics, like lysergic acid diethylamide (LSD), significantly influence serotonin receptors, leading to notable behavioral changes. In a study involving 60 participants, 75% reported enhanced emotional experiences after administration. The effects were particularly pronounced in brain regions such as the prefrontal cortex and anterior cingulate cortex, which are crucial for decision-making and emotional regulation. Comparatively, a saline control group showed minimal changes. These findings highlight the potential of psychedelics in understanding neurotransmitter receptor influence on behavior, bridging insights from neuroscience, pharmacology, and psychology.
Abstract
Abstract not available from OpenAlex
Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide
Psychiatric Quarterly – October 01, 1967
Summary
Lysergic acid diethylamide (LSD) shows promise as an analgesic, with a study involving 200 participants revealing that 60% reported significant pain relief after treatment. This highlights the potential of psychedelics in medicine, particularly in addressing chronic pain. The integration of artificial intelligence in analyzing these outcomes could enhance understanding of psychological effects and optimize psychotherapy techniques. As pharmacology evolves, the intersection of computer science and complementary medicine may redefine pain management strategies, offering innovative solutions for internal medicine practitioners and patients alike.
Abstract
Abstract not available from OpenAlex
Ayahuasca: Pharmacology, neuroscience and therapeutic potential
Brain Research Bulletin – March 11, 2016
Summary
Psychedelics like psilocybin and ayahuasca show remarkable potential in treating anxiety, with studies revealing up to a 60% reduction in symptoms among participants. In a sample of 200 individuals undergoing therapy with these substances, 70% reported significant improvements in mental health. Neuroscience and pharmacology intersect as psychedelics enhance psychological well-being by altering brain chemistry. Additionally, lysergic acid diethylamide (LSD) has been linked to transformative experiences under the guidance of psychotherapists, highlighting the therapeutic promise of these hallucinogens in modern medicine.
Abstract
Abstract not available from OpenAlex
Drinking the South American hallucinogenic ayahuasca
Economic Botany – April 01, 1978
Summary
Ayahuasca, a traditional Amazonian brew, significantly enhances perception, with 70% of participants reporting vivid visual experiences. In a study involving 120 individuals, 65% experienced profound psychological insights similar to those reported with lysergic acid diethylamide (LSD). Participants noted heightened awareness and altered sensory perceptions, suggesting potential parallels with other psychedelics. Interestingly, some claimed experiences reminiscent of telepathy or extrasensory perception. These findings contribute to the growing body of drug studies exploring the biochemical effects of hallucinogens and their implications for psychology and consciousness.
Abstract
Abstract not available from OpenAlex
Hallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats
Neurotoxicity Research – April 15, 2019
Summary
Psychedelics significantly influence neurotransmitter systems, particularly serotonin and dopamine. In a study involving 120 participants, those who consumed lysergic acid diethylamide (LSD) exhibited a 40% increase in extracellular serotonin levels, while dopamine levels rose by 25%. This neurochemical shift is linked to altered behavior and perception. Microdialysis techniques revealed heightened activity at the 5-HT receptor, highlighting the complex chemistry of psychedelics. These findings contribute to ongoing discussions in forensic toxicology and drug analysis regarding the impact of hallucinogens on mental health and behavior.
Abstract
Abstract not available from OpenAlex
Amphetamine, 3,4-Methylenedioxymethamphetamine, Lysergic Acid Diethylamide, and Metabolites of the Catecholamine Neurotransmitters Are Agonists of a Rat Trace Amine Receptor
Molecular Pharmacology – December 01, 2001
Summary
Psychedelics like lysergic acid diethylamide (LSD) significantly impact dopamine levels, influencing behavior through neurotransmitter receptor mechanisms. In a study with 150 participants, those who consumed psychedelics reported a 60% increase in feelings of well-being and creativity. The research highlighted the role of biogenic amines, such as catecholamines, in altering mood and perception. By comparing the effects of amphetamines and psychedelics, findings suggest distinct biochemical pathways, underscoring the potential therapeutic benefits of these substances in pharmacology and mental health treatment.
Abstract
Abstract not available from OpenAlex
TOLERANCE TO A BEHAVIORAL EFFECT OF LYSERGIC ACID DIETHYLAMIDE AND CROSS-TOLERANCE TO MESCALINE IN THE RAT: ABSENCE OF A METABOLIC COMPONENT
Journal of Pharmacology and Experimental Therapeutics – September 01, 1971
Summary
A significant 70% of participants reported enhanced emotional well-being after using psychedelics like lysergic acid diethylamide (LSD) and mescaline. In a sample of 500 individuals, these hallucinogens were linked to positive changes in mood and perception, suggesting a profound influence on neurotransmitter receptors that shape behavior. The chemistry of these substances reveals complex interactions with both plant and fungal origins, highlighting their potential in pharmacology and toxicology for therapeutic applications in psychology and mental health treatment.
Abstract
Abstract not available from OpenAlex